Purple biotech reports potential biomarker data support cm24's mechanism of action

Rehovot, israel, oct. 06, 2023 (globe newswire) -- purple biotech ltd. ("purple biotech" or "the company") (nasdaq/tase: ppbt), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported new biomarker data for its lead oncology drug, cm24, a first-in-class anti-ceacam1 monoclonal antibody. data were presented at the american association for cancer research ( aacr ) special conference: pancreatic cancer in boston in a scientific poster titled: “phase 1 study of cm24 in combination with nivolumab in patients with advanced pancreatic cancer – survival, exploratory biomarkers and effect on neutrophil extracellular traps (nets)”.
PPBT Ratings Summary
PPBT Quant Ranking